Zhejiang AngLiKang Pharmaceutical CO.,LTD. (SHE:002940)
34.17
-1.18 (-3.34%)
Apr 30, 2026, 9:25 AM CST
SHE:002940 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 687.41 | 697.38 | 859.75 | 735.47 | 688.91 |
Trading Asset Securities | 102.26 | 36.04 | 10 | 69.3 | 59.6 |
Cash & Short-Term Investments | 789.67 | 733.42 | 869.75 | 804.76 | 748.51 |
Cash Growth | 7.67% | -15.68% | 8.08% | 7.52% | -12.36% |
Accounts Receivable | 218.89 | 234.32 | 244.86 | 295.51 | 301.32 |
Other Receivables | 2.71 | 9.85 | 21.45 | 6.77 | 17.27 |
Receivables | 221.6 | 244.18 | 266.31 | 302.28 | 318.59 |
Inventory | 447.47 | 503.79 | 393.44 | 293.23 | 299.6 |
Other Current Assets | 27.11 | 17.48 | 32.43 | 51.69 | 9.25 |
Total Current Assets | 1,486 | 1,499 | 1,562 | 1,452 | 1,376 |
Property, Plant & Equipment | 617.28 | 603.86 | 615.8 | 445.7 | 474.63 |
Long-Term Investments | 304.84 | 304.7 | 301.41 | 302.15 | 147.34 |
Goodwill | 312.94 | 312.94 | 312.94 | 21.98 | 21.98 |
Other Intangible Assets | 123.57 | 133.55 | 139.14 | 38.78 | 40.05 |
Long-Term Deferred Tax Assets | 39.12 | 50.06 | 32.77 | 22.44 | 20.65 |
Long-Term Deferred Charges | 52.64 | 49.48 | 35.06 | 0.98 | 1.6 |
Other Long-Term Assets | 14.57 | 21.07 | 20.95 | 312.09 | 1.36 |
Total Assets | 2,951 | 2,975 | 3,020 | 2,596 | 2,084 |
Accounts Payable | 434.09 | 485.45 | 402.49 | 320.45 | 335.97 |
Accrued Expenses | 44.77 | 120.24 | 130.41 | 220.56 | 218.67 |
Short-Term Debt | 137.06 | 163.37 | 134.9 | 171.94 | 1.76 |
Current Portion of Long-Term Debt | 69.74 | 20.21 | 30.4 | 25.02 | - |
Current Portion of Leases | - | - | 0.26 | - | - |
Current Income Taxes Payable | 11.7 | 5.57 | 9.34 | - | 2.88 |
Current Unearned Revenue | 10.41 | 32.31 | 18.72 | 41.67 | 31.9 |
Other Current Liabilities | 105.27 | 16.39 | 5.45 | 8.95 | 4.1 |
Total Current Liabilities | 813.03 | 843.54 | 731.97 | 788.59 | 595.29 |
Long-Term Debt | 242.26 | 303.5 | 423.95 | 150 | - |
Long-Term Unearned Revenue | 17.64 | 16.78 | 17.85 | 9.73 | 13.3 |
Long-Term Deferred Tax Liabilities | 10.67 | 12.29 | 13.95 | 1.6 | 0.06 |
Total Liabilities | 1,084 | 1,176 | 1,188 | 949.93 | 608.64 |
Common Stock | 201.73 | 201.73 | 201.73 | 139.12 | 95.95 |
Additional Paid-In Capital | 708.28 | 684.01 | 723.84 | 782.91 | 824.87 |
Retained Earnings | 794.22 | 712.9 | 674.51 | 577.87 | 478.74 |
Treasury Stock | -84.1 | -74.5 | -20.12 | - | -63.34 |
Comprehensive Income & Other | 7.15 | 6.4 | 6.25 | 2.75 | 2.64 |
Total Common Equity | 1,627 | 1,531 | 1,586 | 1,503 | 1,339 |
Minority Interest | 239.94 | 267.87 | 246.07 | 143.5 | 136.08 |
Shareholders' Equity | 1,867 | 1,798 | 1,832 | 1,646 | 1,475 |
Total Liabilities & Equity | 2,951 | 2,975 | 3,020 | 2,596 | 2,084 |
Total Debt | 449.05 | 487.08 | 589.52 | 346.96 | 1.76 |
Net Cash (Debt) | 340.61 | 246.34 | 280.23 | 457.8 | 746.75 |
Net Cash Growth | 38.27% | -12.10% | -38.79% | -38.69% | -11.34% |
Net Cash Per Share | 1.68 | 1.23 | 1.40 | 2.30 | 3.74 |
Filing Date Shares Outstanding | 211.69 | 196.89 | 199.71 | 197.4 | 197.4 |
Total Common Shares Outstanding | 211.69 | 196.89 | 199.71 | 197.4 | 197.4 |
Working Capital | 672.82 | 655.33 | 829.96 | 663.37 | 780.67 |
Book Value Per Share | 7.69 | 7.77 | 7.94 | 7.61 | 6.78 |
Tangible Book Value | 1,191 | 1,084 | 1,134 | 1,442 | 1,277 |
Tangible Book Value Per Share | 5.63 | 5.51 | 5.68 | 7.30 | 6.47 |
Buildings | - | 447.5 | 435.42 | 314.48 | 319.46 |
Machinery | - | 640.01 | 628.95 | 467.67 | 439.73 |
Construction In Progress | - | 49.6 | 22.52 | 25.33 | 29.94 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.